Genomic and Immunologic Markers of Intrinsic Resistance to Pembrolizumab Monotherapy in Microsatellite Instability-High Gastric Cancer: Observations from a Prospective Phase II Study

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020. CA Cancer J Clin 2020; 70(01): 7-30

[2] Cao M, Li H, Sun D, Chen W.Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40(05): 205-210

[3] Gao K, Wu J.National trend of gastric cancer mortality in China (2003-2015): a population-based study. Cancer Commun (Lond) 2019; 39(01): 24

[4] Feng RM, Zong YN, Cao SM, Xu RH.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond) 2019; 39(01): 22

[5] Kim JY, Shin NR, Kim A.et al.Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol 2013; 47(01): 28-35

[6] Folprecht G.Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. Cancer Commun (Lond) 2019; 39(01): 74

[7] Chang L, Chang M, Chang HM, Chang F.Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol 2018; 26(02): e15-e21

[8] Chao J, Fuchs CS, Shitara K.et al.Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021; 7(06): 895-902

[9] Fuchs CS, Doi T, Jang RW. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018; 4 (05) e180013

[10] Shitara K, Özgüroğlu M, Bang YJ.et al; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392(10142): 123-133

[11] Marabelle A, Fakih M, Lopez J.et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21(10): 1353-1365

[12] Kwon M, An M, Klempner SJ.et al.Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov 2021; 11(09): 2168-2185

[13] Mandal R, Samstein RM, Lee KW.et al.Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 2019; 364(6439): 485-491

[14] Schrock AB, Ouyang C, Sandhu J.et al.Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 2019; 30(07): 1096-1103

[15] Qian J, Nie W, Lu J.et al.Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies. Int J Cancer 2020; 146(11): 3124-3133

RIGHTS & PERMISSIONS

2022 Global Medical Genetics